You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)今日正式被納入港股通名單
格隆匯 09-06 12:11

格隆匯9月6日丨基石藥業-B(02616.HK)宣佈,公司股票已於2021年9月6日正式被納入港股通名單,並於當日生效。這意味着符合相關資格的境內投資者可以通過港股通渠道,對公司股票直接進行交易。

基石藥業董事長兼首席執行官江寧軍博士表示:“基石藥業獲納入港股通充分展現出資本市場對公司實力和價值的認可,我們也期待可以通過港股通進一步擴大內地的投資者基矗基石藥業一直致力於滿足中國和全球癌症患者的殷切醫療需求。未來我們將持續帶來突破性療法,造福更多患者。”

2021年上半年,基石藥業成功上市兩款同類首創的腫瘤精準治療藥物普吉華®(普拉替尼)和泰吉華®(阿伐替尼),並實現了優異的銷售業績。此外,基石藥業還遞交了四項新藥上市申請(“NDA”),兩款同類首創/潛在同類最優的產品艾伏尼布和舒格利單抗獲批在即,凸顯了公司強勁的研發實力和商業化能力。

2022年,公司預計將遞交超過五項NDA申請,並進一步提升創新藥物研發,充分發揮管線2.0的潛力,提交一至兩項具有同類首創/同類最優/第一梯隊潛力和全球權益的高度差異化的新分子臨牀試驗申請,釋放產品組合的全球潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account